Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently sold shares of the company's stock. According to a recent SEC filing, Wolk sold 13,015 ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It is set to report its Q1 2025 earnings on April 15. Wall Street ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

Johnson & Johnson (NYSE ... s top-selling drugs is now facing biosimilar competition, weighing on its stock price growth lately. If you want upside with a smoother ride than an individual stock ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Johnson & Johnson is expected to post earnings ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Johnson & Johnson is expected ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, ...